Cirrhosis News and Research

Latest Cirrhosis News and Research

World Hepatitis Alliance calls for urgent action to address viral hepatitis

On World Hepatitis Day, the World Hepatitis Alliance has called for urgent attention to be given to recent figures showing that although viral hepatitis kills as many as HIV/AIDS, the great majority of countries have no programmes in place to tackle it.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

On World Hepatitis Day (28 July), the World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can cause severe liver infections and lead to 1.4 million deaths every year. Some of these hepatitis viruses, most notably types B and C, can also lead to chronic and debilitating illnesses such as liver cancer and cirrhosis, in addition to loss of income and high medical expenses for hundreds of millions of people worldwide.

24 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Comprehensive analysis of disease burden in US

In nearly every major cause of premature death - from ischemic heart disease to diabetes to interpersonal violence - the United States trails its economic peers, according to new research from a global collaborative of scientists led by the Institute for Health Metrics and Evaluation at the University of Washington.

12 Jul 2013

Research reveals link between elevated BMI and increased risk of gallstone in women

New research reveals a causal association between elevated body mass index (BMI) and increased risk of gallstone disease. Results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show women are at greater risk of developing gallstones.

12 Jul 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Study shows iron-uptake receptor plays a role in HCV infection

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload.

11 Jun 2013

Low levels of vitamin D associated with high levels of hepatitis B virus replication

Researchers from Germany have found that low levels of vitamin D are associated with high levels of hepatitis B virus replication. Findings published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggest seasonal fluctuations in vitamin D and HBV levels point to a link in these variables among patients with chronic HBV.

6 Jun 2013

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen.

3 Jun 2013

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.

1 Jun 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.

22 May 2013

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.

20 May 2013